
|Videos|June 23, 2015
Next Steps Following PALOMA3 Trial for Breast Cancer
Author(s)Massimo Cristofanilli, MD, FACP
Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, Jefferson University Hospital, discusses the next steps following the PALOMA3 trial, which was a randomized, placebo-controlled phase III study examining palbociclib plus fulvestrant in pre- and post-menopausal patients with ER-positive breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































